Cargando…
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma
INTRODUCTION: Patients with follicular lymphoma (FL) receiving third-line or later (3L +) therapy have long survival, which can make estimating long-term overall survival (OS) from trial data challenging. The objective of this study was to estimate long-term OS for mosunetuzumab from the GO29781 tri...
Autores principales: | Sanchez Alvarez, Javier, Jaber, Mahmoud, Blanchet Zumofen, Marie-Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673801/ https://www.ncbi.nlm.nih.gov/pubmed/37851321 http://dx.doi.org/10.1007/s40487-023-00245-4 |
Ejemplares similares
-
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023) -
P1148: REAL WORLD DATA (RWD) AMONG FOLLICULAR LYMPHOMA (FL) PATIENTS IN GERMANY WITH AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY AND COMPARISON WITH CLINICAL DATA FOR MOSUNETUZUMAB
por: Marschner, N., et al.
Publicado: (2022) -
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023) -
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023) -
P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)